ArticleJournal of viral hepatitis2025
Clinical Impact of Continuation Versus Cessation of Antiviral Therapy in Chronic Hepatitis B: A Modelling Study With Implications for Hepatitis B Cure.
Article in Journal of viral hepatitis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare. We simulated the probability of virologic relapse as an exponential decay function from the time of antiviral cessation. We used literature-based estimates for input probabilities following virologic relapse: clinical relapse (60%, conditional on virologic relapse), hepatitis flare (57%, conditional on clinical relapse) and HBsAg-loss (6%-8%). We projected HBsAg loss, cirrhosis, HCC, and survival. In 10 years, cessation strategies would increase cumulative incidence of HBsAg loss from 4.6% to 12.9%-17.3% but would not appreciably change survival (from 90.6% with continuation to 88.1%-89.0%). In an undifferentiated population, continuation would be a preferred strategy to increase average life expectancy (by 0.75-1.05 years) unless HBsAg loss following treatment cessation was > 46%. Sensitivity analyses showed that the decision to continue or stop antivirals would depend on the off-treatment rates of cirrhosis and HCC for people who remain HBsAg-positive but do not fulfil retreatment criteria. Careful selection of people for antiviral cessation using quantitative HBsAg levels could improve survival compared with continuation. Clinical practice guidelines should emphasise selective application of antiviral cessation to persons most likely to lose HBsAg without experiencing liver-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.